Atopic Dermatitis
Conference Coverage
Steroid phobia drives weaker prescribing, nonadherence for AD
The source of these fears can be information from friends, relatives, media, the Internet, as well as doctors.
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
Cosmeceutical Critique
Cupping in dermatology
Over the past decade, the popularity of this ancient procedure has been increasing in the United States.
Latest News
Probiotic LGG doesn’t lessen eczema, asthma, or rhinitis risk by age 7
Study shows no effect when Lactobacillus rhamnosus GG was given in the first 6 months of life. Experts say benefit may lie in a...
Original Research
Review of Ethnoracial Representation in Clinical Trials (Phases 1 Through 4) of Atopic Dermatitis Therapies
Although minority groups are disproportionally affected by atopic dermatitis (AD), they may be underrepresented in clinical trials for AD in the...
Conference Coverage
Global registry tracks COVID-19 outcomes in atopic dermatitis patients
Dupilumab monotherapy was associated with lower odds of hospitalizations compared with other therapies.
Food for Thought
The Impact of Prenatal Nutrition on the Development of Atopic Dermatitis in Infancy and Childhood
We examine the existing literature surrounding maternal diet on the development of atopic dermatitis in infancy and childhood.
Latest News
Managing overuse of food IgE panels: Multiple approaches needed
Beyond wasteful spending, excessive food IgE testing can lead patients to worry needlessly and to avoid foods they aren’t allergic to.
Commentary
Patch Testing on Dupilumab: Reliable or Not?
Patch testing is important to help determine a possible allergic contactant, but there is confusion about its accuracy in patients taking...
Tips
Wet Your Whistles: Alcohol-Induced Flushing With Use of Topical Calcineurin Inhibitors
Localized flushing after alcohol ingestion is a reported adverse effect of 2 topical calcineurin inhibitors, tacrolimus and pimecrolimus, which...
Commentary
An Update on JAK Inhibitors in Skin Disease
In this editorial, we focus on recent trials of JAK inhibitors tested in patients with atopic dermatitis, including topical RUX, as well as oral...